Dr.ย Qingย Zhou
MD, PhD (Oncology)
Professor & Deputy Director, Guangdong Lung Cancer Institute
corporate_fareGuangdong Provincial People's Hospital, Guangzhou
Qing Zhou
MD, PhD (Oncology)
Prof. Qing Zhou is a Professor, MD, PhD and senior lung cancer specialist at Guangdong Provincial People's Hospital and Guangdong Lung Cancer Institute in Guangzhou, China. She serves as Deputy Director of the Guangdong Lung Cancer Institute and Director of the Third Pulmonary Department, Cancer Center. She has been working at the Institute since 2006, building nearly two decades of focused clinical and research expertise in lung cancer.
Prof. Zhou's clinical and academic work centres on precision oncology for lung cancer, with a particular focus on EGFR-mutated non-small cell lung cancer (NSCLC), targeted therapy, immunotherapy, and strategies to overcome resistance to EGFR tyrosine kinase inhibitors. She received her PhD in Oncology from Sun Yat-sen University in 2006 and undertook visiting academic training at the Cancer Center, University of Colorado, USA, in 2009. She has participated in more than 120 multicenter lung cancer clinical trials and served as Principal Investigator in 28 of those trials. She has published more than 80 SCI-indexed research papers, with 26 as first or corresponding author, and holds leadership positions in the Chinese Thoracic Oncology Group and Chinese Society of Clinical Oncology.
CancerFax can coordinate medical-report review and consultation support for international patients seeking access to Prof. Zhou's expertise at Guangdong Lung Cancer Institute.
Why Consider Prof. Qing Zhou?
Prof. Zhou combines nearly two decades of dedicated lung cancer clinical practice with one of China's most active clinical-trial research programmes, making her a highly relevant specialist for patients with advanced or EGFR-driven NSCLC seeking precision oncology expertise.
Areas of Specialization
Precision oncology for lung cancer with a focus on EGFR-targeted and immune-based strategies
Prof. Zhou specialises in the full continuum of lung cancer management, from biomarker-guided diagnosis and treatment selection to advanced targeted therapy, immunotherapy, and resistance-strategy planning.
EGFR-Targeted Therapy & Resistance Strategies
Molecular profiling-guided EGFR-TKI treatment and management of acquired resistance in NSCLC.
- arrow_rightFirst-, second-, and third-generation EGFR-TKI selection based on mutation profile
- arrow_rightOsimertinib and next-generation TKI planning for EGFR-mutated advanced NSCLC
- arrow_rightTreatment strategies for central nervous system metastases in EGFR-positive lung cancer
- arrow_rightMechanisms of acquired resistance to EGFR-TKI therapy
- arrow_rightLiquid biopsy and re-biopsy-guided resistance assessment
- arrow_rightCombination strategies and subsequent therapy planning after resistance
Immunotherapy in Lung Cancer
Evidence-based immunotherapy planning for selected NSCLC patients, guided by biomarker profiling.
- arrow_rightPD-1 and PD-L1 inhibitor selection based on tumour histology and biomarker status
- arrow_rightImmunotherapy in combination with chemotherapy for eligible advanced NSCLC patients
- arrow_rightManagement of immune-related adverse events
Precision & Multidisciplinary Lung Cancer Treatment
Biomarker-driven treatment planning and evidence-based multidisciplinary care for complex lung cancer cases.
- arrow_rightComprehensive molecular profiling including NGS and ctDNA for treatment selection
- arrow_rightTranslational research from basic science to bedside lung cancer practice
- arrow_rightClinical trial-based treatment planning for patients with limited standard options
- arrow_rightCoordinated tumour board review integrating oncology, thoracic surgery, and radiology
- arrow_rightStaging work-up and treatment pathway planning for newly diagnosed lung cancer
- arrow_rightSecond-opinion evaluation for complex or treatment-resistant cases
Procedures & Treatment Approaches
Evidence-based lung cancer treatment across targeted, immune, and systemic modalities
Prof. Zhou delivers comprehensive lung cancer treatment planning, including EGFR-targeted therapy, immunotherapy, chemotherapy combinations, and clinical trial enrolment, guided by molecular profiling and tumour board review.
EGFR-Targeted Therapy Planning
Targeted TherapyMolecular profiling-guided EGFR-TKI selection and resistance-strategy planning for EGFR-mutated NSCLC.
Immunotherapy & Systemic Oncology
Medical OncologyCheckpoint inhibitor-based and combination systemic therapy for eligible advanced NSCLC patients.
Molecular Diagnosis & Biomarker Testing
DiagnosisComprehensive molecular staging and biomarker evaluation to guide precision treatment selection.
Second Opinion & Clinical Trial Evaluation
Second OpinionIndependent expert review for complex lung cancer cases, with assessment of clinical trial eligibility.
Research & Publications
Peer-reviewed contributions to lung cancer precision oncology and clinical trial leadership
Prof. Zhou has published more than 80 SCI-indexed research papers, with 26 as first or corresponding author, covering EGFR-targeted therapy, immunotherapy, resistance mechanisms, and biomarker-guided lung cancer treatment. She has led or participated in more than 120 multicenter clinical trials.
Prof. Zhou's active participation in 120+ multicenter trials means eligible lung cancer patients may be assessed for investigational therapy options through CancerFax coordination.
Education & Training
Prof. Zhou completed her PhD in Oncology at Sun Yat-sen University in 2006 and subsequently undertook visiting academic training at the Cancer Center, University of Colorado, USA.
Clinical Experience
Prof. Zhou has been based at Guangdong Lung Cancer Institute and Guangdong Provincial People's Hospital since 2006, building close to two decades of focused clinical, research, and trial leadership in lung cancer.
Languages & International
Prof. Zhou's consultation language profile has not been publicly confirmed. CancerFax can coordinate professional medical interpreter support for international patients.
CancerFax can coordinate professional medical interpreter support for international patients requiring consultation with Prof. Zhou.
CancerFax coordinates certified medical interpreters for English, Arabic, Russian, and 20+ other languages for international patients consulting at Guangdong Provincial People's Hospital.
How CancerFax Helps You Access Dr. Qing Zhou
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Qing Zhou's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Qing Zhou's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Qing Zhou before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Qing Zhou's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Qing Zhou's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Qing Zhou's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Qing Zhou
Prof. Qing Zhou specialises in lung cancer, particularly non-small cell lung cancer (NSCLC) and EGFR-mutated lung cancer. Her clinical focus includes targeted therapy for EGFR-driven NSCLC, immunotherapy, biomarker-guided precision oncology, and strategies to manage resistance after targeted therapy.
Prof. Zhou is based at Guangdong Provincial People's Hospital in Guangzhou, China, where she serves as Deputy Director of the Guangdong Lung Cancer Institute and Director of the Third Pulmonary Department, Cancer Center. She has been working at the Institute since 2006.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an expert opinion from Prof. Zhou at Guangdong Lung Cancer Institute, subject to hospital availability and case acceptance. Please submit your reports through CancerFax for an initial assessment.
Submit your medical reports using the 'Send Your Reports' button on this page. The CancerFax team will review your documents, prepare a structured case summary, and coordinate the next steps with Guangdong Provincial People's Hospital, subject to availability.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, molecular profiling results, imaging, and prior treatment history. Prof. Zhou's extensive experience in EGFR-targeted therapy and resistance strategies makes her well positioned to provide an independent expert assessment for complex NSCLC cases. The consultation format and availability depend on the hospital's schedule.
Yes. Prof. Zhou has participated in more than 120 multicenter lung cancer clinical trials and has served as Principal Investigator in 28 of those trials. Patients interested in clinical trial options for EGFR-mutated NSCLC or immunotherapy may be assessed for eligibility through CancerFax coordination.
Connect with Qing Zhou Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.